These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

161 related items for PubMed ID: 1642151

  • 1. Suppression of PTH and decreased action on bone are partially responsible for the low calcemic activity of 22-oxacalcitriol relative to 1,25-(OH)2D3.
    Finch JL, Brown AJ, Mori T, Nishii Y, Slatopolsky E.
    J Bone Miner Res; 1992 Jul; 7(7):835-9. PubMed ID: 1642151
    [Abstract] [Full Text] [Related]

  • 2. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Brown AJ, Ritter CR, Finch JL, Morrissey J, Martin KJ, Murayama E, Nishii Y, Slatopolsky E.
    J Clin Invest; 1989 Sep; 84(3):728-32. PubMed ID: 2760211
    [Abstract] [Full Text] [Related]

  • 3. The effect of 22-oxacalcitriol on serum calcitriol.
    Dusso AS, Negrea L, Finch J, Kamimura S, Lopez-Hilker S, Mori T, Nishii Y, Brown A, Slatopolsky E.
    Endocrinology; 1992 Jun; 130(6):3129-34. PubMed ID: 1597134
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
    Finch JL, Brown AJ, Slatopolsky E.
    J Am Soc Nephrol; 1999 May; 10(5):980-5. PubMed ID: 10232683
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. 1,25 dihydroxyvitamin D3 alone or in combination with parathyroid hormone does not increase bone mass in young rats.
    Gunness-Hey M, Gera I, Fonseca J, Raisz LG, Hock JM.
    Calcif Tissue Int; 1988 Nov; 43(5):284-8. PubMed ID: 3145794
    [Abstract] [Full Text] [Related]

  • 9. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia.
    Slatopolsky E, Finch J, Ritter C, Denda M, Morrissey J, Brown A, DeLuca H.
    Am J Kidney Dis; 1995 Nov; 26(5):852-60. PubMed ID: 7485144
    [Abstract] [Full Text] [Related]

  • 10. [Appositional rate of incisor dentin and hematic calcium level in rats. Application of time marking method using lead acetate].
    Matsumoto S.
    Aichi Gakuin Daigaku Shigakkai Shi; 1990 Dec; 28(4):1225-35. PubMed ID: 2135153
    [Abstract] [Full Text] [Related]

  • 11. Role of 1,25-dihydroxyvitamin D on the skeletal resistance to parathyroid hormone.
    Galceran T, Martin KJ, Morrissey JJ, Slatopolsky E.
    Kidney Int; 1987 Dec; 32(6):801-7. PubMed ID: 3430963
    [Abstract] [Full Text] [Related]

  • 12. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
    Takahashi F, Finch JL, Denda M, Dusso AS, Brown AJ, Slatopolsky E.
    Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
    [Abstract] [Full Text] [Related]

  • 13. Regulation of intestinal vitamin D receptor expression in experimental uraemia: effects of parathyroidectomy and administration of PTH.
    Szabó A, Schmutz A, Pesian S, Schmidt-Gayk H, Ritz E, Reichel H.
    Nephrol Dial Transplant; 1998 Feb; 13(2):340-9. PubMed ID: 9509444
    [Abstract] [Full Text] [Related]

  • 14. The noncalcemic analogue of vitamin D, 22-oxacalcitriol, suppresses parathyroid hormone synthesis and secretion.
    Nishii Y, Abe J, Mori T, Brown AJ, Dusso AS, Finch J, Lopez-Hilker S, Morrissey J, Slatopolsky E.
    Contrib Nephrol; 1991 Feb; 91():123-8. PubMed ID: 1800003
    [Abstract] [Full Text] [Related]

  • 15. The mechanism for the disparate actions of calcitriol and 22-oxacalcitriol in the intestine.
    Brown AJ, Finch J, Grieff M, Ritter C, Kubodera N, Nishii Y, Slatopolsky E.
    Endocrinology; 1993 Sep; 133(3):1158-64. PubMed ID: 8396012
    [Abstract] [Full Text] [Related]

  • 16. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy.
    Rodriguez M, Felsenfeld AJ, Llach F.
    Kidney Int; 1991 Dec; 40(6):1063-8. PubMed ID: 1762307
    [Abstract] [Full Text] [Related]

  • 17. Human parathyroid hormone (1-34) and salmon calcitonin do not reverse impaired mineralization produced by high doses of 1,25 dihydroxyvitamin D3.
    Gunness-Hey M, Hock JM, Gera I, Fonseca J, Poser J, Bevan J, Raisz LG.
    Calcif Tissue Int; 1986 Apr; 38(4):234-8. PubMed ID: 3085902
    [Abstract] [Full Text] [Related]

  • 18. The activity of 22-oxacalcitriol in osteoblast-like (ROS 17/2.8) cells.
    Pernalete N, Mori T, Nishii Y, Slatopolsky E, Brown AJ.
    Endocrinology; 1991 Aug; 129(2):778-84. PubMed ID: 1649745
    [Abstract] [Full Text] [Related]

  • 19. Is skeletal response to parathyroid hormone abnormal in experimental renal failure?
    Patel S, Hsu CH.
    J Lab Clin Med; 1988 Sep; 112(3):387-93. PubMed ID: 3411200
    [Abstract] [Full Text] [Related]

  • 20. On the mechanisms for the selective action of vitamin D analogs.
    Dusso AS, Negrea L, Gunawardhana S, Lopez-Hilker S, Finch J, Mori T, Nishii Y, Slatopolsky E, Brown AJ.
    Endocrinology; 1991 Apr; 128(4):1687-92. PubMed ID: 2004595
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.